Inhibikase Therapeutics Inc

NAS:IKTHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$1.67+1.52%LiveIn session · ≈ AED 6.13 · Market cap $233.02M · Next earnings Fri 13 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	−28.0%	−266.4%	94.6%	−5,127.8%	—	—	—	—
Operating margin	−403.5%	−476.2%	−14,686.2%	−7,712.0%	—	—	—	—
Net margin	−407.7%	−476.9%	−14,625.9%	−7,304.8%	—	—	—	—
EBITDA margin	0.0%	0.0%	−14,620.4%	−7,236.7%	—	—	—	—
Return on equity	−29.1%	−38.5%	−85.8%	−173.3%	−29.0%	−27.9%	−27.9%	+0.0 pts
Return on assets	−19.3%	−34.8%	−72.4%	−131.2%	−27.9%	−26.6%	−26.6%	+0.0 pts
Return on capital employed	−28.0%	−38.4%	−85.3%	−181.5%	−30.1%	−30.1%	—	—
Debt / equity	0.0×	0.0×	0.0×	0.1×	0.0×	0.0×	0.0×	—
Debt / assets	2.2%	0.6%	1.4%	4.3%	0.1%	0.0%	—	—
Interest coverage	−95.9×	−741.2×	−243.5×	0.0×	0.0×	0.0×	—	—
Current ratio	3.1×	10.5×	6.6×	4.1×	26.4×	21.7×	21.7×	+0.0%
Quick ratio	3.1×	10.5×	6.6×	4.1×	26.4×	21.7×	—	—
Cash ratio	3.0×	10.1×	1.9×	2.7×	15.1×	16.8×	16.8×	+0.0%
Asset turnover	0.0×	0.1×	0.0×	0.0×	0.0×	0.0×	—	—
Receivables turnover	—	28.2×	3.1×	—	—	—	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.